CRISPR Therapeutics, Anagenesis Announce Collaboration
News Jun 09, 2016
CRISPR Therapeutics and Anagenesis Biotechnologies has announced a strategic in-licensing and collaboration agreement, which grants CRISPR Therapeutics exclusive worldwide license to Anagenesis’ proprietary Paraxial Mesoderm Multipotent Cells (P2MCs) technology for cell therapy for all human muscle diseases. The P2MC technology allows for the efficient, reproducible and chemically defined differentiation of pluripotent cells into skeletal muscle stem cells, also known as satellite cells. The agreement will support the advancement of CRISPR-based cellular therapies for the treatment of musculoskeletal diseases. Initial research will focus on Duchenne Muscular Dystrophy (DMD).
“We are highly committed to finding new treatments for DMD and this collaboration is an important building block in support of our broader research strategy within DMD and other musculoskeletal diseases,” said Samarth Kulkarni, Chief Business Officer of CRISPR Therapeutics.
Anagenesis’ proprietary P2MC technology was developed with the support of AFM-telethon, INSERM-Transfert, CNRS and Université de Strasbourg. This technology, in combination with CRISPR/Cas9 gene editing, has the potential to yield important new treatments for boys with DMD, and for patients with other muscle disorders.
“Bringing together the CRISPR gene editing platform with the P2MC technology enables us to develop ex vivo therapeutic approaches for the treatment of DMD using muscle satellite stem cells,” said Bill Lundberg, M.D., Chief Scientific Officer of CRISPR Therapeutics.
“We are excited to partner with CRISPR Therapeutics, a leader in the field of CRISPR gene editing, to advance therapeutic development for musculoskeletal diseases, including DMD, where there is a high unmet medical need,” said Jean-Yves Bonnefoy, PhD, President and Chief Executive Officer of Anagenesis. “We believe our P2MC technology has a unique advantage and provides strong synergy with CRISPR Therapeutics’ gene editing technology. This partnership will be a cornerstone for our newly formed cell therapy-focused US subsidiary, Anagenesis Biotherapies Inc., located in Boston.”
Anagenesis is the third collaboration for CRISPR Therapeutics in the past seven months, and follows agreements with Vertex Pharmaceuticals and Bayer AG. Each collaboration allows the company to access distinctive capabilities to bring new, potentially transformative gene-based medicines to patients with serious diseases. As part of this collaboration, Olivier Pourquié, PhD, scientific founder of Anagenesis and professor at Harvard Medical School and the Brigham and Women’s Hospital, will serve as a consultant to CRISPR Therapeutics
Non-Coding DNA Variants Increase Autism RiskNews
Whilst the contribution of gene variants to autism risk is well-established, the contribution of the 98% of the genome that does not code for gene sequences is still relatively unknown. Now, a new study has identified regulatory elements as potential genetic risk factors.READ MORE
Comments | 0 ADD COMMENT
International Conference on Analytical and Bio Analytical Techniques
Oct 31 - Nov 01, 2018